Abstract
HUGE POTENTIAL
The global market for in vitro diagnostics (IVD) in 2007 is estimated to be
US$34 billion and we expect growth to be around 9% annually.
Although in vitro diagnostics influence more than 60% of clinical decisions,
IVD sales represent only a small proportion of total healthcare expenditures;
in 2005 IVD sales in Europe totalled less that 2% of total healthcare
expenditure. However, clinicians are under increasing pressure for better
clinical outcomes and to control cost through efficient disease management.
The early detection and treatment of long-term conditions is critical, and
modern, fast and effective diagnostics are essential to meeting these aims.
INNOVATION IS DRIVING CHANGE
For example, molecular diagnostics is the fastest growing segment of clinical
diagnostics with a growth rate of around 10-15% and is estimated to be worth
approximately US$2.4 billion.
By detecting DNA and RNA sequences characteristic of bacteria, viruses or
cells, molecular diagnostics has applications in a wide variety of disorders
including infectious diseases, cancer and cardiovascular. Molecular diagnostic
testing is often complex and usually carried out in a lab environment. The
trend and challenge is to create testing products which provide fast and
accurate results in a clinical setting.
This is a competitively hot area with Beckman Coulter, Becton Dickinson,
Siemens, bioMérieux, Roche and Gen-Probe all involved.
For Each Company
- Overview
- Products/Technologies
- Major Developments Mergers, acquisitions and alliances
- Financial Performance(where available)
All major IVD sectors are covered
- Clinical Chemistry
- Immunochemistry
- Haematology/Haemostasis
- Microbiology
- Molecular Diagnostics
- Point of Care
View Cart
